Close Menu

NEW YORK (GenomeWeb) – Lucence Diagnostics said today that it has entered a partnership with genetic testing lab Bangkok Molecular Genetics to make its blood-based cancer diagnosis and screening tests available to patients in Thailand.

Under the terms of the agreement, BMG will distribute Lucence's blood tests, which involve the detection of DNA fragments shed by a tumor into the blood and target the most common cancers in Asia, such as breast, colon, lung, and nasopharyngeal cancer.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.